|
А.Н. Родионов
Городской кожно-венерологический диспансер, Санкт-Петербург
В начало...
В начало...
1. Машкиллейсон А.Л. Лечение кожных болезней: Руководство для врачей. М:Медицина 1990;560.
2. Шахтмейстер И.Я., Шварц Г.Я. Новые лекарственные препараты в дерматологии. М 1995;32 - 38.
3. Farber E.M., Nall M.L. The natural history of psoriasis in 1500 patients. Dermatologica 1974;148:1 - 18.
4. Camp R.D.R. Psoriasis. In:Textbook of dermatology. 5-th Ed. Eds. R. Champion, J. Butron, F.J.G. Ebling. Oxford: Blackwell Scientific Publications 1991;1391 - 1457.
5. Verbov J. Psoriasis in chieldhood. Arch Dis Child 1992;67:75 - 76.
6. Christofers E., Sterry W. Psoriasis. In: Dermatology in general medicine. 4-th ed. Eds. A.Z. Fitzpathrich Essen, K. Wolff et al. New York: Mc Graw Hill Inc 1993;489 - 514.
7. Van Scott E.J., Ekel T.M. Kinetics or hyperplasia in psoriasis. Arch Dermatol 1963;88:373 - 381.
8. Weinstein G.D., van Scott E.G. Autoradiographic analysis or turnover times of normal and psoriatic epidermis. J Invest Dermatol 1965;45:257 - 262.
9. Weinstein G.D., Frost P. Abnormal cell proliferation in psoriasis. J Invest Dermatol 1968;50:254 - 259.
10. Weinstein G.D. et al. Proliferative defects in psoriasis, in Psoriasis - Cell Prolifiration. Eds N.A. Wright, R.S. Camplejohn.
Edinburg - New York: Charhill Hivingstone 1983;189.
11. Weinstein G.D., Mc Culloch J.L., Ross P.A. Cell kinetic basis for pathophesiology of psoriasis. J Invest Dermatol 1985;85:579 - 585.
12. Lever W., Schoumburg-Zever G. Histopathology of the skin. 6-th ed. Philadelphia: J.B. Lippencott Company 1983;139 - 147.
13. Berth-Jenes J. Calcipotriol in dermatology. Br J Clin Practice 1996;Suppl 83:1 - 33.
14. Lea A.P., Goa K.L. Calcipotriol: a review of it's pharmacological properties and therapeutic efficacy in the management of psoriasis. Clin Immunother 1996;5:230 - 248.
15. Berth-Jenes J., Fletcher A., Yutchinson P.E. Epidermal cytokeratin and immune responses during treatment of psoriasis with calcipotriol and betametasone valerate. Br J Dermatol 1992;126:356 - 361.
16. de Jong E.M.G., van de Kerkhof P.C.M. Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long-term treatment with vitamin D3 analogue mc 903: modulations and interrelations. Br J Dermatol 1991;124:221 - 229.
17. Kragballe K., Fogh K., Sogaard H. Long-term efficacy and tolerability of topical calcipotriol in psoriasis. Results of an open study. Acta Dermatol 1991;71:475 - 478.
18. van de Kerkhof P.C.M., van Erp P.E.J. Calmodulin levels are grossly elevated in the psoriatic lession. Br J Dermatol 1983;165:217 - 218.
19. de Mare S., de Jong E.M.G.J., van der Kerkhof P.C.M. DNA content and Ks8. 12 binding of the psoriatic lesion during treatment with the vitamin D3 analog Mc 903. Br J Dermatol 1990;123:291 - 295.
20. Holland D.B., Roberts S.G., Russell A. et al. Changes in epidermal levels during treatment of psoriasis with the topical vitamin D3 analog MC 903. Br J Dermatol 1990;122:284.
21. Gerritsen M.J., Rulo H.F., van Vlijmen-Willems I. et al. Topical treatment of psoriatic plaques with 1,25-dihyrdoxyvitamin D3: a cell biological study. Br J Dermatol 1993;128:666 - 673.
22. Baker B., Fry L. The immunology of psoriasis. Br J Dermatol 1992;126:1 - 9.
23. Phillips W.G., Breathnach S.M. Psoriasis: immune indicators and treatment. Clin Immunother 1994;1:157 - 167.
24. Jack D.B. Unravelling mechanisms of disease and treatment in psoriasis. Inpharma 1995;9:9 - 10.
25. Mozzanica N., Cattaneo A., Schmitt E. et al. Topical calcipotriol for psoriasis - an immunohistologic study. Acta Dermatol 1994;Suppl 186:171 - 172.
26. Finzi A.F. A controlled multicentre study comparing the efficacy and safety of calcipotriol with a combination of betamethasone dipropionate/salicylic acid (abstract). Calcipotriol: a Vitamin D Analogue for the Treatment of Psoriasis. Satellite Symposium of the Third Congress of the European Academy of Dermatology and Venerology. Copenhagen 1993.
27. Ramirez-Bosca A. et al. A study of local immunity in psoriasis. Br J Dermatol 1988;119:587.
28. Chin J.H. et al. Lymphocyte adhesion to psoriatic dermal endothelium: Mechanisms and modulation. J Invest Dermatol 1990;95:29.
29. Heng M.C. et al. High endothelial venules in involved and unenvolved psoriatic skin: Recognition by homing receptors on cytotoxic T lymphocytes. Br J Dermatol 1990;118:315.
30. Cooper K.D., Baadsgaard O. Immunologic features of psoriasis in Immunologic Diseases of the skin. Ed. R.E. Jordan. Norwalk Appleton a Langa 1990;611.
31. Kawohl G. et al. Polymorphonuclear leucosyte Chemotaxis in psoriasis: Enhaucemant by self-activaled serum. Br J Dermatol 1980;103:527.
32. Lingnom M.L., Chersetich I., Lotti T. et al. Treatment of psoriasis vulgaris with topical calcipotriol: is the clinical improvement of lesional skin related to a down-regulation of some cell adhesion molecules? Acta Dermatol 1994;Suppl 186:55 - 57.
33. Muller K., Svenson M., Bendtzen K. 1a,25-Digidroxyvitamin D3and a novel vitamin D analogue MC 903 are potent ingibitors of human interleikin 1 in vitro. Immunol Left 1988;17:361 - 365.
34. Barker H., Wilkinson D.S. Psoriasis. In: Textbook of Dermatology. 3-d ed. Eds. A. Rook, D.S. Wilkinson, F.J.G. Ebling. Oxford - London: Blackwell Scientific Publications 1979;1315 - 1362.
35. Muller K., Diamant M., Bentzen K. Ingibition of production and function of interleukin-6 by 1a,25-Digidroxyvitamin D3. Immunol Lett 1991;28:115 - 120.
36. Oxholm P., Staberg B. et al. Expression of interleukin-6-like molecules and tumour necrosis factor after topical treatment of psoriasis with a new vitamin D analoque (MC 903). Acta Dermatol 1989;69:385 - 390.
37. Bagot M., Charue D., Pamphile R., Revus J. Immunosupressive effects of 1 a,25-Digidroxyvitimin D3 analogue (calcipotriol) of epidermal cells. In: Vitamin D: gene regulation, structure-function analysis and clinical application. Berlin: de Gruyter 1991;518 - 519.
38. Hustmyer F.G., Benninger L., Manjlagas S.C. Comparison of the effects of 22-oxa-1,25(OH) 2D3 and MC 903 on the production of IL-6, Y IFN and lymphocyte proliferation in peripheral blood mononuclear cells. J Bone Miner Res 1991;6:S292.
39. Reitamo S., Remitz A., Gloriso L. et al. Induction of IL-8 gene with cyclosporine and vitamin D in vitro [abstract]. Clin Res 1993;41:466A.
40. Kemeny L., Kenderessy A.S., Olasz E. et al. The interleukin-8 receptor: potential target for antipsoriatic therapy? Eur J Pharmacol 1994;13:258:260 - 272.
41. Larsen C.G., Kristensen M., Patudan K. et al.
1,25(OH) 2D3 regulator of interleukin-8 expression and production. Biochem Biophys Res Commun 1993;176:1020 - 1026.
42. Koli K., Kekski-Oja J. Vitamin D3 and calcipotriol enchance the secretion of transforming growth factor-b1 and -b2 in culturedmurine keratinocytes. Growth Factors 1993;8:153 - 163.
43. Koli K., Kekski-Oja J. 1,25-digidroxyvitamin D3 enhances the expression of transforming growth factorb-1 and its latent formbinding protein in cultured breast carcinoma cells. Cancer Res 1995;1:55:1540 - 1546.
44. Jehan F., Naveu I., Barbot N. et al. MC903, and analogue of 1,25-digidroxyvitamin D3, increases the synthesis of nerve growth factor. Fur J Pharmacol Mol Pharmacol 1991;14:208:189 - 191.
45. Koli K., Kekski-Oja J. Vitamin D3 and calcipotriol decrease extracellular plasminogen activator activity in cultured keratinocytes. J Invest Dermatol 1993;101:706 - 712.
46. Krueger G.G., Eyre R.W. Trigger factors in psoriasis in Dermatology Clinics. Eds. G. Weinstein, J. Voorhees. Philadelphia: Saunders 1984;373.
47. Holick M.F., MacLaughlin J.A., Clark M.B. et al. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science 1980;210:203 - 205.
48. DeLuca H.F. The metabolism, physiology and function of Vitamin D. In: Vitamin D, Basic and Clinical Aspects. Ed. R. Kumar. Boston: Hague Nijhoff 1984;1 - 68.
49. Holick M.F. Vitamin D: biosynthesis, metabolism and mode of action. In: Endocrinology. Grune and Stratton. Ed. L.J. De Groot. New York 1989;902 - 926.
50. Bell N.H. Vitamin D. Endocrine System. J Clin Invest 1985;76:1 - 6.
51. Hosomi J., Hosoi J., Abe E. et al. Regulation of terminal differentiation of cultured mouse epidermal cells by 1 alpha, 25-dihydroxyvitamin D3. Endocrinology 1983;113:1950 - 1957.
52. Smith E.L., Walworth N.C., Holick M.F. Effect of 1 alpha, dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes growth in serum-free conditions. J Invest Dermatol 1986;7:709 - 714.
53. Marx S., Eil C. Nuclear uptake of 1,25-dihydroxy[3H] cholecalciferol in dispersed fibroblasts cultured from normal human skin. Proc Natl Acad Sci USA 1981;78:2562 - 2566.
54. Kragballe K. Vitamin D3 and skin diseases. Arch Dermatol Res 1992;284:Suppl:S30 - S36.
55. McLaughlin J.A., Gange W., Taylor D. et al. Cultured psoriatic fibroblasts from involved and uninvolved sites have a partual but not absolute resistance to the prolifiration-inhibition activity of 1,25-dihidroxyvitamin D3. Proc Natl Acad Sci USA 1985;82:5409 - 5412.
56. Morimoto S., Yoshikawa K., Kozuka T. et al. An open study of vitamin D3 treatment in psoriasis vulgaris. Br J Dermatol 1986;115:421 - 429.
57. McLane J.A., Kim H.-J., Abdelkader N., Katz M. 1,25(OH) 2D3 enhances antiproliferative effect and transcription of TGF-beta 1 on human keratinocytes. In: Vitamin D: gene regulation structure-function analysis and clinical application. Eds. A.W. Norman, R. Boullin, M. Thomasset. Berlin: de Gruyter 1991;426 - 427.
58. Tang W., Ziboh V.A. Agonist/inositol triphosphate-induced release of calcium from murine keratinocytes: a possible link with keratinocyte differencation. J Invest Dermatol 1991;96:134 - 138. 59. Serensen H., Binderup L., Calverley M.J. et al. In vitro metabolism of calcipotriol (MC903), a vitamin D analogue. Biochem Pharmacol 1990;39:391 - 393.
60. Kragballe J., Beck H.-J., Segaard H. Improvement of psoriasis by a topical vitamin D3 analoque (MC 903) in a double-blind study.
Br J Dermatol 1988;223 - 230.
61. Kragballe K. Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (Mc 903). Arch Dermatol 1989;125:1647 - 1652.
62. Holick M.F. Wii 1,25-dihydroxyvitamin D3, Mc 903; and their analogues herald a new pharmacologic era for the treatment of psoriasis? [comment]. Arch Dermatol 1989;125:1692 - 1697.
63. Lagner S., Verjans H., Stapor V. et al. Treatment of chronic plague psoriasis by 1a, 25-dihydroxyvitamin D3 analogue (MC
903) in a double-blind study. Br J Dermatol 1988;119:223 - 230.
64. Morimoto S., Kumahara Y. A patient with psorisis curred by 1a-hydroxyvitamin D3. Med J:Osaka Univ 1985;35 - 51.
65. Feldman D., Chen T., Hirst M. et al. Demonstration of 1,25-dihydroxyvitamin D3 receptor in human skin biopsies. J Clin Endocrinol Metab 1980;51:1463 - 1465.
66. Berg J.P., Liane K.M., Bjorhovde S.B. et al. Vitamin D receptor binding and biological effecs of cholecalciferol analoques in rat thyroid cells. J Steroid Biochem Mol Biol 1994;50:145 - 150.
67. Valaja T., Mahonen A., Pirskanen A. et al. Affinity of MC 903 for 1,25-dihydroxyvitamin D receptor and its effects in the synthesis of osteocalcium in human osteosarcoma cells. Biochem Pharmacol 1990;15:40:1827 - 1832.
68. Milde P., Hauser U., Simon T. et al. Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J Invest Dermatol 1991;97:230 - 239.
69. Carlberg C., Mathiasen I.S., Saurat J.-H. et al. The 1,25-dihydroxyvitamin D3 (VD) analogues MC 903. EB 1089 and KH
1060 activate the VD receptor: homodimers show higher ligand sensitivity than heterodimers with retinoid X receptors. J Steroid Biochem Mol Biol 1994;51:137 - 142.
70. Ozono K., Sone T., Pike J.W. The genomic mechanism of action of 1,25-dihydroxyvitamin D3. J Bone Miner Res 1991;6:1021 - 1027.
71. Bittiner B., Bleehan S.S., MacNeil S. 1a,25-(OH)
2-vitamin D3 increases intracellular calcium in human keratinocites. Br J Dermatol 1991;124:230 - 235.
72. Pillai S., Bikle D.D., Elias P.M. 1,25-dihydroxyvitamin D production and receptor binding in human keratinocytes varies with differentation. J Biol Chem 1988;263:5390 - 5395.
73. MacLaughlin J.A., Cantley L.C., Holick M.F. 1,25-(OH)2 D3 increase calcium and phosphatidylinositol metabolism in differentiating cultured human keratinocytes. J Nutr Biochem 1990;1:81 - 87.
74. Yada Y., Ozeki T., Meguro S. Signal transduction in the onset of terminal keratinocyte differenciation induced by 1a,25-(OH) 2-vitamin D3: role of protein kinase C translocation. Biochem Biophys Res Commun 1989;163:1517 - 1522.
75. Woodley D.T., Demarchez M., Sengel P. et al. The control of cutaneus development and bichavior: the influence of extracellular and soluble factors. In: Dermatology in general medicine.
3-d ed. Eds. T. Fitzpathick, A.Z. Essen, K. Wolff et al. New York: Graw-Hill Inc 1987;132 - 146.
76. Hennings H. et al. Calcium regulation of growth and differentiation of mouse epidermal cells in culture. Cell 1980;19:245.
77. Hennings H. et al. Intercellular calcium alterations in response to increased calcium in normal and neoplastic keratinocytes. Carcinogenesis 1989;10:777.
78. Yuspa S.H. et al. Epidermal cell culture. Transplan Proc 1980;12:144.
79. Regnier M., Darmon M. 1,25-dihydroxyvitamin D3 stimulates specifically the last steps of epidermal differentiation of cultured human keratinocytes. Differentiation 1991;47:173 - 188.
80. Lee S.C., Ikai K., Ando Y., Imamura S. Effects of 1a,25-dihydroxyvitamin D3 on the transglutaminase activity of transformed mouse epidermal cells in culture. J Dermatol 1989;16:7 - 11.
81. Muller K., Heilmann C., Poulson L.K. et al. The role of monocytes and T-cells in 1,25-dihydroxyvitamin D3 mediated inhibition of B cell function in vitro. Immunopharmacol 1991;21:121 - 128.
82. Limat A., Hunziker T., Braathen L.R. Effects of 1a-25-dihydroxyvitamin D3 and calcipotriol on organotopic cultures of outer root sheath cells: a potential model to evaluate antipsoriatic drugs. Arch Dermatol Res 1993;285:402 - 409.
83. Trydal T., Lillehaug J.R., Aksnes L. et al. Regulation of cell growth, vitamin D3 receptor in C3H/
c-myc, mRNA, and 1,25-(OH) 2 10T1/2 mouse embryofibroblasts by calcipotriol and 1,25-(OH) 2 vitamin D3. Acta Endocrinol (Copenh) 1992;126:75 - 79.
84. Kissmeyer A.M., Binderup L. Calcipotriol (MC 903): pharmacokinetics in rats and biological activities of methabolistes - a comparative study with 1,25-dihydroxyvitamin D3. Biochem Pharmacol 1991;1:41:1601 - 1606.
85. Binderup L., Bramm E. Effects of a novel vitamin D analogue MC
903 on cell prolifiration and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 1988;37:889 - 895.
86. Kragballe K., Wildfang I.L. Calcipotriol (MC 903), novel vitamin D analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res 1990;282:164 - 167.
87. Takamoto S., Onishi T., Morimoto S. et al. Effect of 1a-hydroxycholecalciferol on psoriasis vulgaris: a pilot study. Calc Tissue Int 1986;39:360 - 364.
88. Gerritsen M.J.P., Boezeman J.B.M., van Vlijmen-Willems I.M.J.J. et al. The effect of tacalcitol 1,24-(OH) 2D3 on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: a placebo-controlled, double-blind study. Br J Dermatol 1994;131:57 - 63.
89. Binderup L.A. Novel vitamin D analogue with potent effect of cell prolifiration and cell differentication. In: Vitamin D: Molecular, cellular and clinical endocrinology. Eds. A.W. Norman, K. Scheaefer, H.G. Grigolelt, D. Hitrrath. Berlin: de Gruyter 1988;300 - 309.
90. Kissmeyer A.M., Binderup L. Calcipotriol (MC 903): pharmacokinetics and biological activities of metabolities. Biochem Pharmacol 1991;41:1601 - 1606.
91. Staberg A.M., Roed-Peterson J., Menne T. Efficacy of topical treatment in psoriasis with MC 903, a new vitamin D analogue.
Acta Dermatol 1989;69:147 - 150.
92. Berth-Jones J., Hutchinson P.E. Efficacy and Safety of calcipotriol. Rev Contemp Pharmacother 1992;3:367 - 375.
93. Highton A., Quell J. and the Calcipotrien Study Group. Calcipotrien ointment 0.005% for psoriasis: a safety and efficacy study. J Am Acad Dermatol 1995;32:67 - 72.
94. Wehr R., Gibson J., Epinette et al. The safety of topically applied calcipotrien ointment 0.005% (a vitamin D3 analogue), as mesiured by blood, urine, and bone density analysis in psoriatic patients. Skin Pharmacol 1992;5:206 - 207.
95. Murdoch D., Clissold S.P. Calcipotriol: a review of its pharmacological properties and therapeutic use in psoriasis vulgaris. Drugs 1992;43:415 - 429.
96. Tool J.W.P. Mechanism of action of calcipotriol in the therapy of psoriasis. Can J Dermatol 1993;5:385 - 388.
97. Holick M., Pochi P., Bhawan J. Topically applied and orally administered 1,25-dihydroxyvitamin D3 ia s novel. Safe, and effective therapy for the treatment of psoriasis: a three year experience and histologic analysis. J Invest Dermatol 1989;446.
98. Norman A.W., Buillon R., Thomasset M. Effect of calcipotriol on psoriasis: a double-blind, placebo-controlled study of calcipotriol (MC 903) and calcium metabolism. Vitamin D: gene regulation, structure-function analysis and clinical application. Proceedings of the eight workshop on vitamin D. Paris - Berlin: de Gruyter 1991.
99. Dovonex ointment (calcipotriol). Curr Probl Pharmacoving 1994;20:3.
100. Dubertret L., Wallach D., Souteyrand P. et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blined, right-left comparative, vehicle-controlled study. J Am Dermatol 1992;27:Pt1:983 - 988.
101. Harrington C., Austad J., Goldin D. et al. Efficacy and safety aspects of calcipotriol cream in the treatment of psoriasis vulgaris [abstract]. Calcipotriol: a Vitamin D Analogue for the treatment of Psoriasis, Satellite Symposium of the Third Congress of the European Academy of Dermatology and Venerology. Copenhagen 1993.
102. Highton A., Quell J., Calcipotriene S.G. et al. Calcipotriene ointment 0,005% for psoriasis: a safety and efficacy study. J Am Acad Dermatol 1995;32:67 - 72.
103.Lebwohl M.G. The evolution of vitamin D analogues for the treatment of psoriasis [editorial]. Arch Dermatol Res 1995;131:1323 - 1324.
104. Kragballe K. Safety spects of calcipotriol treatment [abstract]. Acta Dermatol 1994;Suppl 186:44.
105. Binderup L., Latini S., Binderup E. et al. 20-epivitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem Pharmacol 1991;41:1569 - 1575.
106. Gumvski-Sunek D., Rizzoli R., Saurat J.H. Calcium tolerance test in patients with extended body surface psoriasis and treated with calcipotriol. Dermatology 1992;185:229 - 230.
107. Masuda S., Strugnell S., Calverley M.J. et al. In vitro metabolism of the antipsoriatic vitamin D analog, calcipotriol, in two cultured human keratinocyte models. J Biol Chem 1994;269:4794 - 4803.
108. Green C., Ganpule M., Harris D. et al. Comparative effects of calcipotriol (MC 903) solution and placebo (vehicle of MC 903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994;130:483 - 487.
109. Buillon R., Allewaert K., Xiang D.Z. et al. Vitamin D analogs with low afficity for the vitamin D binding protein: enchanced in vitro and decreased in vivo activity. J Bone Miner Res 1991;1051 - 1057.
110. Lebwohi M., Berman B., France D.S. Addition of short cintact anthralin therapy to an ultraviolet B phototherapy regimen: assessment of efficacy. J Am Acad Dermatol 1985;13:780 - 784.
111. Palleschi G.M., Gentili A., Caproni M. et al. Structural alterations of basal keratinocytes and capillary loop in psoriasis during treatment with topical calcipotriol. Acta Dermatol 1994;Suppl 186:49 - 51.
112. Veyron P., Pamphile R., Binderup L., Touraine J.L. Immunological properties of 1,25-dihydroxyvitamin D3 analogues: a strong effect on the prolongation of mouse skin allograft survival. In: Vitamin D: gene regulation structure-function analysis and clinical application. Eds. A.W. Norman, R. Boullin, M. Thomasset. Berlin:Gruyter 1991.
113. Bagot M., Charue D., Lescs M.C. et al. Immunosupressive effects of 1,25-dihydroxyvitamin D3 and its analogue calcipotriol in epidermal cells. Br J Dermatol 1994;130:424 - 431.
114. Ramsay C.A., Berth-Jones J., Brundin G. et al. Long-term use of topical calcipotriol in chronic plague psoriasis. Dermatology 1994;189:260 - 264.
115. Poyner T., Hughes I.W., Dass B.K., Adnitt P.I. Long-term treatment of chronic plaque psoriasis with calcipotriol. J Dermatol Treat 1993;4:173 - 177.
116. Ellis J.P., Griffiths W.A.D., Klaber M.R. Long-term treatment of chronic plaque psoriasis with calcipotriol ointment in patients unresponsive to short-contract dithranol. Eur J Clin Res 1995;7:247 - 257.
117. Katz H.I., Watson M.J. Long-term efficacy and safety of calcipotriol in the treatment of psoriasis vulgaris [abstract].
118. Cullen S.I., Gainesville Fla and Calcipotriol study group. Long-term Effectiveness safety of topical calcipotriene for psoriasis. South Med J 1996;89:1053 - 1056.
119. Binderup L. Comparison of calcipotriol with selected metabolities and analogues of vitamin D3: effects in cell growth regulation in vitro and calcium metabolism in vivo. Pharmacol Toxicol 1993;72:240 - 244.
120. Medansky R.S., Greenspan A., Kraus S.J. et al. The comparative efficacy of differasone diacetat ointment 0.05% vs. Calcipotriene ointment (Dovonex) in the treatment of psoriasis. J Geriatr Dermatol 1996;4:20 - 24.
121. Berth-Jones J., Bourke J.F., Elouzi H. et al. Immediate and long-term effects of topical calcipotrial on calcium homeostasis during treatment of psoriasis [abstract]. Br J Dermatol 1992;127:Suppl 40:17 - 18.
122. Saurat J.H., Sunek D.G., Rizzoli R. Topical calcipotriol and hypercalcemia [letter]. Lancet 1991;337: 1287.
123. Mortensen L., Kragballe K., Wegmann E. et al. Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect in calcium or bone metabolism. Arandomized, double-blined, placebo-controlled study. Acta Venerol 1993;73:300 - 304.
124. Gumowski-Sunek D., Rizzoli R., Saurat J.H. Oral calcium tolerance test in extensive psoriasis treated with topical calcipotriol. Dermatology 1995;190:43 - 47.
125. Gumowski-Sunek D., Rizzoli R., Saurat J.H. Effects of topical calcipotriol on calcium metabolism in psoriatic patients: comparison with oral calcipotriol. Dermatologica 1991;183:275 - 279.
126. Berth-Jones J., Bourke J.F., Igbal S.J. et al. Urine calcium excretion during treatment of psoriasis with topical calcipotriol. Br J Dermatol 1993;129:411 - 414.
127. Liao W.C., Kripalani K., Natarajan C. et al. Percutaneous absorption of 3H-calcipotriene ointment in healthy male volunteers and male psoriatic patients [abstract]. Clin Res 1993;41:497A.
128. Rougier A., Loue C., Maibach H.I. In vivo percutaneous penetration of some organic compounds related to anatomic situ in humans: perspective assessment by the stripping method. J Pharm Sci 1986;76:451 - 454.
129. Sorensen A., Binderup L., Calverly M.G. et al. In vitro metabolism of calcipotriol (MC 903), a vitamin D analogue. Biochem Pharmacol 1990;39:391 - 393.
130. Dwyer C., Chapman R.S. Calcipotriol and hypercalcemia. Lancet 1991;338:764 - 765.
131. Kragballe K., Gjertsen B.T., de Hoop D. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991;337:193 - 196.
132. Cunliffe W.J., Derth-Jones J., Claudy A. et al. A multicanter comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointments in patients with psoriasis vulgaris. J Am Acad Dermatol 1992;26:736 - 743.
133. Scarpa C. Calcipotriol: clinical trial versus betamethasone dipropionate + salicylic acid. Acta Dermatol (Stockh) 1994;74:Suppl 186:47.
134. Bruce S., Epinette W.W., Funecella T. et al. Comparative study of calcipotriene (MC 903) ointment and fluorcinplonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994;31:755 - 759.
135. Berardesca E., Vagnoli G.P., Faranelli N. et al. Topical calcipotriol vs clobetasol: instrumental findings. Acta Dermatol (Stockh) 1994;74:Suppl 186:178.
136. Nielsen P.G. Calcipotriol or clobetasol propionate occluded with a hydrocolloid dressing for treatment of psoriasis [letter]. Acta Dermatol (Stockh) 1993;73:394.
137. Klaber M.R., Hutchinson P.E., Pedvis-Leftick A. et al. Comparative effects of calcipotriol solution (50m/ml) and betamethasone17-valerate solution (1 mg/ml) in the treatment of sculp psoriasis. Br J Dermatol 1994;131:678 - 683.
138. van de Kerkhof P.C.M. Calcipotriol cream and concurrent corticosteroids in psoriasis [abstracts]. J Eur Acad Derm 1995;5:Suppl 1:S184.
139. Lebwohl M., Siskin S.B., Epinette W. A multicenter trial of calcipotriol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996;35:268 - 269.
140. Yarrisongton C.I. Cost effectiveness analysis of calcipotriol ointment and "short-contact" ditranol in treatment mildto moderate psoriasis.Br J Med Econ 1995;8:27 - 32.
141. Berth-Jones J., Chu A.C., Doud W.A.F. et al. A multicenter, parallel-group comparison of calcipotriol ointment and short contact ditranol therapy in chronic plaque psoriasis. Br J Dermatol 1992;127:266 - 271.
142. Ellis J.P., Gribbins W.A.D., Klaber M.R. Long-term treatment of chronic plaque psoriasis with calcipotriol ointment in patients unresponsive to short contact dithranol. Eur J Clin Res 1995;7:247 - 257.
143. Tham S.N., Lun K.C., Cheong W.K. A comparative study of calcipotriol ointment and tar chronic plaque psoriasis. Br J Dermatol 1994;131:673 - 677.
144. Pinheiro N., De R.N. Comparative effects of calcipotriol ointment (50mg/g) and 5% coal tar/2% allantion/0,5% hydrocortisone creamin trating plaque psoriasis. Submitted for publication 1995.
145. Kragballe K. Combination of topical calcipotriol (MC 903) and UVB radiation of Psoriasis vulgaris. Dermatologica 1990;181:211 - 214.
146. Kokelj F., Lavaroni G., Guadarnini A. UVB versus UVB plus calcipotriol (MC 903) therapy for psoriasis vulgaris. Acta Dermatol (Stockh) 1995;75:386 - 387.
147. Kerscher M., Volkenandt M., Plewig G., Lehmann P. Combination phototherapy of psoriasis with calcipotriol and narrow-band UVB
[letter]. Lancet 1993;342:923.
148. Efficacy and safety of calcipotriol in combination with UVB therapy. Third Congress of the European Academy of Dermatology and Venerology. Copenhagen 1993.
149. Austad J. Treatment of psoriasis with calcipotriol + UVB light versus monotherapy with calcipotriol or UVB [abstract]. Calcipotriol in Combination with Phototherapy Satellite Symposium, 27-th Nordic Dermatology Congress 1995.
150. Molin L., van Weelden H., Austad J. et al. Does UVB improve the effect of calcipotriol in psoriasis? [abstract]. Calcipotriol Rational, Efficacy and Safety, Proceeding of the 2-nd International Symposium on Calcipotriol. Monte Carlo 1993.
151. Hecker D., Lebwohl M. Topical calcipotriene in Combination with UVB phototherapy for psoriasis. Int J Dermatol 1997;36:302 - 303.
152. Calcipotriol in combined therapies. Third Congress of the European Academy of Dermatology and Venerology. Copenhagen 1993.
153. Frappaz A., Thiovolet J. Calcipotriol in combination with PUVA: a randomized double-blind placebo study in severe psoriasis.
Eur J Dermatol 1993;351 - 354.
154. Speight E.L., Farr P.M. Calcipotriol improves the response of psoriasis to PUVA. Br J Dermatol 1994;130:79:28.
155. Quirino A.P., Resende C., Mesquita-Guimaraes G. PUVA e calcipotriol topico na psoriase vulgar. Psoriase Rev 1995;1:15 - 22.
156. Grossman R.M., Thivolet J., Claudy A. et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994;31:68 - 74.
157. Gupta S., Fass D., Shimizu M. et al. Potentiation of immunosupressive effects of cyclosporine A by 1a, 25-dihydroxyvitaminD3. Cell Immunol 1989;121:290 - 297.
158. Gepner P., Amor B., Fournier C. 1,25-Dihydroxyvitamin D3 potentiales the in vitro inhibitory effects of cyclosporine A on T-cells from rheumatoid artritis patients. Artritis Pheum 1989;32:31 - 36.
159. Bagot M., Charue D., Pamphilie R. et al. Calcipotriol potentials the immunosuppressive effects of cyclosporine A in allogenic reactions [abstract]. J Unvest Dermatol 1991;96:1023.
160.Veyron P., Pamphile R., Binderup L. et al. Immunological properties of 1,25 vitamin D3 analogues: a strong effect in the prolongation of mouse skin allograft survival. In: Vitamin D: gene regulation, structure-function analysis and clinical application. Preceedings of the Eight Workshop on vitamin D. Eds. A.W. Norman, R. Bouillon, M. Thomasset. Paris - New York 1991.
161. Van de Kerkhof P.C.M., Hutchinson P.E. and the calcipotriol study group. Topical use of calcipotriol improves outcome in acitretin treated patients with severe psoriasis vulgaris. Br J Dermatol 1996;135: Suppl 47:30.
162. Yip J., Hoodfield M. Contact dermatitis from MC 903, a topical vitamin D3 analoque. Contact Dermatitis 1991;25:139 - 140.
163. Bruynzeel D.P., Hol C.W., Nieboer C. Allergic contact dermatitis to calcipotriol [letter]. Br J Dermatol 1992;127:66.
164. de Groot A.C. Contact allergy to calcipotriol. Contact Dermatitis 1994;30:242 - 243.
165. Steinkjer B. Contact dermatitis from calcipotriol. Contact Dermatitis 1994;31:122.
166. Georgala S., Rigopoulos D., Aroni K. et al. Generalized pustular psoriasis precipitated by topical calcipotriol cream. Int J Dermatol 1994;33:515 - 516.
167. Calcipotriol - headaches. Bull SADRAC 1995; 64.
168. Gray J. Calcipotriol in psoriasis. Update 1994;1;49:548 - 552.
169.McKenna K.E., Stern R.S. Photosensitivity assotiated with combined UVB and calcipotriol therapy. Arch Dermatol 1995;131:1305 - 1307.
170. Kokelj F., Lavaroni G., Perkan V. et al. Hyperprigmentation due to calcipotriol (MC 903) plus heliotherapy in psoriatic patients. Acta Derm (Stockh) 1995;Suppl 75:307 - 309.
171. Murdoch D., Clissoid S.P. Calcipotriol: a review of pharmacological properties and therapeutic use psoriasis vulgaris. Drugs 1992;43:415 - 429.
172. Vilplana J., Mascaro J.M., Lecha M. et al. Low irritancy of 2 day occlusive patch test with calcipotriol cream. Contact Dermatitis 1994;30:45 - 46.
173. Darley C.R., Cunliffe W.J. et al. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris [abstract]. Br J Dermatol 1993;129:Suppl 42-33.
174. Oranje A.P., Marcoux D., Svensson A. et al. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol 1997;203 - 208.
175. van der Kerkhof P.S.M., Witten-Rost M., Gerritsen M.J.P. et al. Possible indications for vitamin D3 analogues in cases other than psoriasis vulgaris. J Dermatol Treat 1996;7:195 - 198.
176.Kurkcuoglu N., Celebi C.R. Confluent and reticulated papillomatosis: response to topical calcipotriol. Dermatology 1995;191:341 - 342.
177.Berth-Jones J., Bourke J., Bailey K. et al. Generalised pustular psoriasis: response to topical calcipotriol. Br Med J
1992;305:868 - 869.
178. Keohane S.G., Cork M.J. Treatment of Grover's disease with calcipotriol (Dovonex). Br J Dermatol 1995;832 - 833.
179. Gray J.D., Bottomley W., Layton A.M. et al. The use of calcipotriol in HIV-related psoriasis. Clin Exp Dermatol 1992;17:342 - 343.
180. Delfino M., Fabbrocini G., Sammarco E. et al. Efficacy of calcipotriol versus lactic acid cream in the treatment of lammelar and X-linked incthyoses. J Dermatol Treat 1994;5:151 - 152.
181. Lucker G.P.H., van der Kerkhof P.C.M., van Dijk M.R. et al.
Effect of topical calcipotriol on congenital ichthyoses. Br J Dermatol 1994;131:546 - 550.
182. Gatti S., Carrozzo A.M., Orlandi A. et al. Treatment of inflammatory linear verrucous epidermal nervus with calcipotriol. Br J Dermatol 1995;132:837 - 839.
183. Harwood C.A., Sloane J., Cook M.G. et al. Calcipotriol in mycosis fungoides [abstract]. Br J Dermatol 1995;133:Suppl 45:43. 184. Kokelj F., Lavaroni G., Piraccini B.M. et al. Nail psoriasis treated with calcipotriol (MC 903): an open study. J Dermatol Treat 1994;5:149 - 150.
185. van de Kerkhof P.C., Steijlen P.M. Topical treatment of psoriasis rubra pilaris with calcipotriol. Br J Dermatol 1994;130:675 - 678.
186. Lucker G.P.H., van de Kerkhof P.C.M., Cruysberg J.R.M. et al.
Topical treatment of Sjogren-Larsson syndrome with calcipotriol. Dermatology 1995;190:292 - 294.
187. Harrison P.V., Stollery N. Disseminated superficial actinic porokeratosis responding to calcipotriol [letter]. Clin Exp Dermatol 1994;19:95.
188. de Jong E.M.G.J., Rulo H.F.C., van de Kerkhof P.C.M. Inflammatory verrucous epidermal nervus (ILVEN) versus linear psoriasis; a clinical histological and immunohistochemical study. Acta Dermatol (Stockh) 1991;71:343 - 346.
189. Berth-Jones., Hutchinson P.E. Alopecia totalis does not respond to topical application of the vitamin D analogue calcipotriol. Dermatol Treat 1991;1:293 - 294.
190. Bottomley W.W., Jotley J., Wood E.J. et al. The effect of calcipotriol on lesional fibroblasts from patients with active morphoea. Acta Dermatol (Stockh) 1995;Suppl 75:363 - 366.
191. Kuypers A., van Dooren-Greebe R.J., van de Kerkhof P.C.M. Acrodermatitis continua Hallopeau: response to combined treatment with acitretin and calcipotriol ointment. Dermatology (in press). 192. Kragballe K., Steylen P.M., Ibsen H.H. et al. Efficacy, tolerability and safety of calcipotriol ointment in disorders of keratinization. Arch Dermatol 1995;131:556 - 560.
Написать комментарий
| 
